Lupin gets 2 observations from USFDA for its Goa facility
Mumbai: Soon after the inspection of its facility in Madhya Pradesh, the Mumbai-based, Lupin Ltd recently got a couple of key observations for it's Goa facility from the United States Food and Drug Administration (USFDA). The US health regulator has completed the inspection of its Goa Facility with two observations.
Drug firm Lupin on Friday said the US health regulator has completed the inspection of its Goa facility and made two key observations.
In a BSE filing, Lupin said, "The observations are procedural in nature and the company is confident of addressing them satisfactorily."
Also Read: Lupin gets 22 observations for MP plant
The United States Food and Drug Administration (USFDA) had carried out the inspection at the Goa manufacturing facility between January 28 and February 8 of this year, it said.
The inspection at the Goa facility closed with two observations, it added.
The company, however, did not disclose the details of observations made by the USFDA.
Lupin was founded in 1968 by Desh Bandhu Gupta. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
Also Read: Lupin gets 6 observations from USFDA for its Pithampur Unit-2
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd